10th November 2019 - 12.30 PM to 2.30 PM
Westin Hotel - 10 Huntington Ave Boston
Rooms: Gloucester / Newbury

ENYO PHARMA

FXR agonist targeting HBV: a new therapeutic class?

A Lunch Event during AASLD Annual Meeting

*During this 2-hour event the goal will be to present **virological and clinical** aspects, provide **recent insights** about the **replication of HBV** and how the key factors could be exploited in the evolving field of new drugs aiming for a **functional cure**. The presentation will be led by the following KOLs :*

Prof. Fabien Zoulim (Inserm Lyon)
General overview of the HBV replication, the role of HBx and cccDNA as targets in the landscape of new HBV treatments

Prof. Stephan Urban (Heidelberg University)
Update on HBV transcription regulation - ready as a target for therapeutic intervention?

Prof. Robert Gish (HepB Foundation)
Presentation of the EYP001 FXR agonist phase 1b data as an example of a new therapeutic option in development

The lunch will only be provided through registration.
To book a place, please send a message to aasld@enyopharma.com

This affiliate event is not an official function/event of the American Association for the Study of Liver Diseases